Curam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Curam

Property Description
Active ingredients Amoxicillin, Clavulanic acid
Generic Name Co-amoxiclav
Form Tablets, Oral Suspension, Injection
Pharmacological Class Systemic Anti-infective (β-lactam/β-lactamase inhibitor)
Origin Semi-synthetic

Curam is the trade name for a combination systemic anti-infective belonging to the penicillin class of antibiotics. It is a prescription-only medicine designed to address and eliminate a wide range of bacterial infections throughout the body, utilizing a dual-component strategy for enhanced efficacy. This product is derived through chemical synthesis and is defined by its two synergistic active components.


What Type of Medicine is Curam and What is it Made Of?

Curam is generically known as Co-amoxiclav, signifying its core composition. The medicine contains two distinct active ingredients: Amoxicillin and Clavulanic acid (supplied as potassium clavulanate). The final product is a synthetic compound derived from the basic penicillin nucleus, and its combination identity distinguishes it from simpler treatments like Amoxicillin monotherapy.

The dual nature of the composition is critical: Amoxicillin provides the primary bactericidal activity, and Clavulanic acid functions as a specialized protective agent known as a β-lactamase inhibitor. This approach is clinically recognized for successfully treating infections when resistance is a concern.


Available Forms and General Therapeutic Purpose

Curam is supplied in multiple dosage form(s) to accommodate various administration routes, which include film-coated tablets and powder for oral suspension for oral intake, as well as a powder for solution for injection/infusion for intravenous administration. This combination is an anti-bacterial for systemic use, intended to treat infections. This provides a necessary and robust solution against infections that might be resistant to antibiotics used alone.

Regulatory References

  1. EMA Public Summary for Co-amoxiclav

What side effects are possible with Curam?

Possible Side Effects and Safety Information

The safety profile of Curam (Co-amoxiclav) is formally classified in regulatory documents according to the frequency and system-organ class affected. Diarrhoea is the only adverse reaction classified as Very Common.

Frequency Classification Examples of Officially Listed Adverse Reactions
Common (ge 1/100 to <1/10) Mucocutaneous candidosis, Nausea, Vomiting
Uncommon (ge 1/1,000 to <1/100) Dizziness, Headache, Skin rash, Pruritus, Transient rise in liver enzyme levels (AST/ALT)

Serious adverse reactions, though rare, are explicitly documented, including life-threatening Hypersensitivity Reactions such as Anaphylaxis and severe cutaneous adverse reactions like Stevens-Johnson Syndrome (SJS). Hepatitis and Cholestatic Jaundice are also listed as serious potential effects, which may occasionally have a delayed onset, appearing after treatment has ended.

Safety notes for specific populations include that hepatic events are reported to occur predominantly in males and older patients, and patients with impaired renal function are recognized as being at greater risk of adverse reactions. The medicine is formally contraindicated in individuals with a history of penicillin hypersensitivity and in those who have previously experienced Co-amoxiclav-associated liver impairment. Furthermore, the label notes that concurrent use with allopurinol may increase the incidence of allergic skin reactions. This structured framework defines the recognized risks and safety boundaries of the medication.

Overdose and Emergency Response

The official regulatory profile for Curam overdose indicates that signs of excessive exposure typically begin with severe gastrointestinal symptoms, including diarrhea, vomiting, abdominal pain, and sleepiness. These manifestations often necessitate medical attention due to a resulting disturbance of fluid and electrolyte balances.

Official Overdose Complications
Amoxicillin Crystalluria: A severe and documented risk is the formation of amoxicillin crystals in the urinary tract. This may lead to greatly decreased urination or cloudy urine, and in some cases, acute renal failure.
Neurological Toxicity: Convulsions (seizures) may occur in severe cases or in individuals with impaired renal function, as this condition affects drug clearance.

When to Seek Urgent Medical Help

No specific antidote is known for Curam overdose. Immediate medical attention is required for all suspected cases. Regulatory authorities mandate that emergency services be contacted immediately if severe signs are present, such as a seizure, collapse, or evidence of profound respiratory distress. Treatment is symptomatic and supportive, focusing on correcting fluid imbalances and ensuring adequate urinary output. The drug components can be removed from the bloodstream using haemodialysis.

Therapeutic Uses of Curam

What Curam Treats: Main Uses and Benefits

Curam (Co-amoxiclav) is a combination systemic anti-infective, generally used to address a wide range of bacterial conditions where symptomatic support is appropriate. The medication is used to address bacterial conditions and is applied to ease the symptom burden associated with acute infection. The medicine is commonly used for infections of the middle ear, sinuses, lungs, skin, urinary tract, and joints.

The medicine is relevant for conditions marked by increased physiological stress, including pneumonia, pyelonephritis (kidney infection), cellulitis, and dental abscesses. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, including those resulting from animal or human bites, and it is applied in settings where the prevention of infection is appropriate before major surgical procedures.

“The treatment supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Support for Systemic and Localized Discomfort Curam is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive, such as fever, inflammation, and pronounced localized pain associated with the infection. This supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Curam

Regulatory authorities define strict population-based rules for the use of Curam (Co-amoxiclav), establishing which patients are eligible, restricted, or absolutely contraindicated from receiving the medicine.

Eligibility Scope Regulatory Status
Populations for whom use is allowed Adults and adolescents (ge 40 kg); Children ge 3 months; Older adults without severe renal impairment.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to any penicillin or other beta-lactam agent (e.g., cephalosporins). Patients with a history of jaundice or hepatic dysfunction previously associated with Co-amoxiclav use.
Populations for whom use is not recommended Patients with suspected Infectious Mononucleosis or Lymphatic Leukaemia (due to rash risk). Pregnant women (use only if clearly needed).

Age-Related and Condition-Specific Eligibility Rules:

  • Pediatric Use: The medicine is approved for children beginning at three months of age; specific formulations are used based on weight. Safety and effectiveness of certain higher-dose or extended-release formulations are not established in all pediatric groups.
  • Organ Function: Severe renal impairment (creatinine clearance le 30 mL/min) requires restricted use and conditional adjustments, as the drug is primarily eliminated through the kidneys. Hepatic impairment requires caution and monitoring.
  • Reproductive Status: Use during pregnancy is not recommended unless determined to be essential. The medicine is compatible with breastfeeding, though caution is advised due to trace excretion that may cause sensitisation in the infant.

What should I know about interactions with other medicines?

Curam, which contains amoxicillin and clavulanic acid, can interact with certain other medications, potentially altering the effects of either drug. It is important to discuss all prescription and non-prescription medicines, supplements, and herbal products with a healthcare provider.

Potential Drug Interactions

Interacting Product Category Potential Effect & Clinical Note
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding. Close monitoring of the patient's coagulation status (INR/prothrombin time) is essential, and the anticoagulant dose may need adjustment.
Probenecid Concurrent use is not recommended because it leads to prolonged and higher blood levels of the amoxicillin component. This occurs due to reduced kidney excretion of amoxicillin.
Methotrexate Increased concentration of methotrexate in the body, potentially leading to greater toxicity. This is due to the amoxicillin component reducing methotrexate's clearance by the kidneys. Close monitoring is advised.
Allopurinol Increased risk of developing an allergic skin rash (hypersensitivity reaction) compared to taking Curam alone.

Curam may also affect the results of certain laboratory tests, such as false-positive results for glucose in the urine when using non-enzymatic methods. Patients taking combination oral contraceptives should be aware that Curam may theoretically reduce their efficacy, requiring the use of a reliable barrier method.

Mechanism of Action

Curam's mechanism of action is defined by a dual-mechanism approach that targets key nodes in signal generation and transmission. The primary component acts via Reversible Non-competitive Inhibition of the COX-2 enzyme, a critical step in the Prostaglandin Synthesis Pathway. This reduces the local biochemical generation of mediators associated with nociceptor activation, resulting in an alteration of the peripheral signal input to the central nervous system.

Simultaneously, the secondary component exerts its effect through Negative Allosteric Modulation of Voltage-gated Ca^2+ channels, influencing central pathways. This action decreases the release of neurotransmitters responsible for signal propagation, thereby influencing the signal transmission and gain characteristics within the nervous system. This integrated strategy addresses both peripheral signal generation and central signal gain, contributing to the overall physiological effect profile.

Dosage and Administration Information

How Curam is Used: Official Administration Guidelines

Curam (Co-amoxiclav) is administered according to specific, standardized instructions, addressing the route, timing, and dosage for proper use.

Administration Scope

Feature Official Administration Instruction
Route of Administration The medicine is officially approved for Oral intake (as tablets, extended-release tablets, or suspension) and for Intravenous (IV) injection or infusion.
Dosing Schedule & Frequency Dosing is typically two or three times daily (every 12 or 8 hours). Standard adult oral doses range from 500 mg/125 mg up to 875 mg/125 mg of the amoxicillin/clavulanic acid combination.
Timing in relation to meals Oral formulations must be administered at the start of a meal or snack. This is a specific condition to enhance the absorption of the clavulanic acid component.
Duration of Course Treatment courses typically range from 7 to 10 days. Therapy should not be extended beyond 14 days without official review of the patient's condition.

Official Procedural Conditions

Official instructions detail requirements for specific patient populations and dosage forms:

  • Tablet Handling: Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed to maintain their intended release profile.
  • Renal Impairment: Dose adjustments are mandatory for patients with reduced kidney function (Creatinine Clearance le 30 mL/min), often requiring a reduced dose or frequency to prevent drug accumulation. The 875 mg/125 mg tablet is not recommended in this population.
  • Pediatrics: Dosing for children weighing le 40 kg is calculated based on body weight (mg/kg/day) and divided into the prescribed dose intervals.

These official administration conditions define the protocol for using Curam, governing not only how often and how long it is taken but also the form and adjustments necessary for different patient circumstances.

Recent Clinical Evidence

Curam: Recent Clinical Evidence

Curam (Co-amoxiclav) was studied for its use across various bacterial conditions. This overview details the structure of the clinical research, the types of patient outcomes that were monitored, and areas where research reports describe that information remains limited or uncertain. This summary is based only on regulatory documents and peer-reviewed scientific literature.


Evidence for Use in Respiratory Infections

For conditions like Community-Acquired Pneumonia and acute exacerbations of chronic bronchitis, the research was primarily built on Randomized Controlled Trials (RCTs) involving adult outpatients and hospitalized patients. These studies monitored clinical resolution rates and bacteriological clearance, often using other established antibiotics as a comparator. Follow-up durations were limited primarily to the immediate post-treatment phase, meaning long-term effects are not fully established regarding infection recurrence.

Research has also explored its use for Acute Bacterial Sinusitis and Acute Otitis Media in various age groups. Studies monitored how symptoms evolved and focused on achieving microbiological eradication. Regulatory documents note that research in these areas explored specific outcomes in scenarios where the infection may involve bacteria that are resistant to common antibiotics used alone.


Evidence for Skin, Soft Tissue, and Other Uses

Research was explored in comparative trials for Skin and Soft Tissue Infections (SSTIs) and Urinary Tract Infections (UTIs), including pyelonephritis. These studies examined measurements of clinical cure and bacteriological clearance. Comparative evidence is lacking against some newer antibiotic classes, and the general applicability of older research may be challenged by data showing patterns related to increasing global antibiotic resistance.

For Surgical Prophylaxis in specific dental procedures, single-dose RCTs examined whether giving the medicine before a procedure was associated with patterns of lower post-operative infection rates. However, follow-up durations were limited to the few days immediately after the operation.


Evidence Gaps: What Remains Uncertain

Specific research has evaluated outcomes in pediatric age groups and older adult patients, but data for certain groups remain insufficient, particularly for high-risk patients with complex co-existing conditions. As most modern studies rely on comparison against active controls (not placebo), comparative evidence is lacking for a direct understanding of outcomes when the infection is left untreated.

Frequently Asked Questions (FAQ)

Common questions about Curam (FAQ)


Q: What is the main reason a doctor might prescribe Curam?

A: Curam is officially indicated for the short-term treatment of a wide range of bacterial infections across the body. According to regulatory documents, this includes infections affecting the lower and upper respiratory tract (like pneumonia and sinusitis), the skin and soft tissues, and the urinary tract. As a combination antibiotic, it is often prescribed to treat infections that may involve bacteria resistant to amoxicillin alone.

Q: Is Curam the same type of medication as [similar medicine name]?

A: Curam is the trade name for the generic combination known as Co-amoxiclav, which belongs to the penicillin class of antibiotics. It is classified as a systemic anti-infective. This means it is designed to kill bacteria throughout the body and uses two components: amoxicillin for primary action and clavulanic acid to protect the amoxicillin from being broken down by certain resistant bacteria.

Q: What are some common reasons people stop taking Curam?

A: Patients may need to stop taking the medicine due to experiencing certain adverse reactions. Official product information highlights that common side effects like severe diarrhea, nausea, or a persistent skin rash can lead to discontinuation. Furthermore, serious adverse events, such as signs of allergic reactions or liver problems, are conditions that regulatory information notes may necessitate stopping the medicine.

Q: Does Curam affect my ability to drive or operate machinery?

A: Regulatory information indicates that the medicine can cause side effects like dizziness or headache in some individuals. If symptoms like dizziness or headache are experienced, regulatory guidance suggests caution, as these effects may affect the ability to drive or operate machinery.

Q: Are there any known long-term side effects associated with Curam?

A: The medicine is generally prescribed for short-term use, typically not exceeding 14 days. However, regulatory warnings note that certain hepatic events (liver problems) may have a delayed onset, sometimes appearing days or weeks after the course of treatment has been completed. This is why vigilance for symptoms like jaundice is mentioned even after treatment is finished.

Q: Is it common to feel tired or fatigued when taking Curam?

A: Official reports and clinical studies have listed fatigue as a potential side effect of the medicine. While not classified as a 'very common' side effect like diarrhea, it is a recognized symptom that may be experienced during the treatment course.

Q: Can I take Curam if I am already taking over-the-counter pain relievers?

A: No major interaction is generally reported between this antibiotic and common pain relievers such as acetaminophen (paracetamol). Information regarding use with other products notes that a review of all current medications, including over-the-counter products, helps ensure proper use and safety.

Q: How does Curam interact with common supplements like multivitamins?

A: Official drug interaction lists primarily focus on prescription medicines like anticoagulants and methotrexate. No major interaction is typically reported between amoxicillin/clavulanic acid and common multivitamins. Disclosure of all supplements being taken is necessary for proper review before starting any antibiotic course.

Q: What happens if I miss a scheduled dose of Curam?

A: According to the official patient information, the dose should be taken as soon as the patient remembers it. However, if it is almost time for the next scheduled dose, the individual should skip the missed dose and continue with the regular schedule. Official guidance notes that a double dose should not be taken to compensate for a missed dose.

Q: What should I know about taking Curam with alcohol?

A: The official product information does not contain an absolute prohibition against moderate alcohol consumption. However, because alcohol may worsen common side effects like dizziness and nausea, and can stress the liver, official guidance often suggests limiting or avoiding alcohol during treatment.

Q: How long does Curam stay in the body after the last dose?

A: The active ingredients in Curam are eliminated relatively quickly. According to official pharmacokinetic data, the medicine has a mean elimination half-life of approximately one hour in healthy individuals. The majority of the active ingredients are typically excreted from the body within a few hours following the last dose.

Q: Is there a generic version of Curam available?

A: Yes, Curam is the brand name for the generic combination of amoxicillin and clavulanic acid, which is known globally as Co-amoxiclav. This combination medicine is widely available under numerous generic and other brand names in different markets.

Q: What does 'contraindication' mean in relation to Curam?

A: A contraindication is a specific condition or circumstance that makes the use of a medicine improper or risky. For Curam, the major contraindications defined in regulatory documents include a history of severe allergic reactions to penicillin antibiotics or any past liver problems (hepatic dysfunction or jaundice) associated with previous Co-amoxiclav use.

Q: What percentage of people experience the most common side effect of Curam?

A: The most common side effect listed in the official product information is diarrhea. This effect is classified as 'Very Common,' meaning it affects more than 1 in 10 patients (over 10%). Specific regulatory documents may provide a precise percentage from clinical trials, but the official classification confirms its high frequency.

Q: Why is Curam sometimes referred to by a different brand name?

A: Due to international marketing and manufacturing, the same active ingredients (amoxicillin and clavulanic acid) are sold under many different brand names worldwide. Regulatory bodies approve these different names, such as Augmentin or Clavulin, while the medication's core function and chemical composition remain the same.

Q: What does the drug's patient information leaflet say about overdose?

A: Official information regarding overdose indicates that it can lead to symptoms such as severe gastrointestinal issues and disturbances in the body’s fluid balance. Regulatory warnings specify that in cases of impaired kidney function or very high doses, more serious effects, such as convulsions, may occur.

Q: Can men and women use Curam differently?

A: There are no differences in the standard dosing or administration protocol specified for men versus women. However, official safety notes do mention that serious liver events associated with the drug have been reported to occur predominantly in males and older patients.

Q: What information should I provide to my doctor before starting Curam?

A: Official regulatory guidance outlines the information that should be reviewed with a healthcare professional before the medicine is started. Key information to review includes any history of allergic reactions to penicillin or other antibiotics, any past issues involving the liver or kidneys, and a history of or suspected glandular fever.

Q: Does Curam carry any specific warnings for people with heart conditions?

A: Regulatory documents do not typically list cardiovascular-specific warnings as a major concern for this particular antibiotic. The primary consideration for patients with conditions like heart failure is the potential for co-existing kidney impairment, as dosage adjustments are necessary when kidney function is reduced.

Q: What are the risks associated with abruptly stopping Curam?

A: Official regulatory information emphasizes the importance of completing the entire prescribed course of the antibiotic, even if symptoms show early improvement. Abruptly stopping the treatment against medical advice can lead to the infection coming back or, potentially, the development of antibiotic-resistant bacteria.

How should Curam be stored and disposed of?

Storage and Disposal of Curam

Official regulatory labeling dictates specific storage conditions for Curam (amoxicillin/clavulanic acid) based on the formulation.


Storage by Formulation

Product Form Temperature Requirement Additional Handling
Tablets / Dry Powder Store below 25 C (77 F) Protect from light and moisture; keep in original container.
Reconstituted Suspension Store in a refrigerator (2 C to 8 C) Do not freeze; discard any unused portion after seven days of preparation.

Disposal and Child Safety

Curam must be kept out of the sight and reach of children. Unused or expired medicine must not be discarded in household waste or flushed down wastewater. Patients are instructed to consult a pharmacist regarding proper disposal methods, which helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Curam found in:

A-Z Index: